IV Double and Triple Concentrated Nicardipine for Stroke and ICH

Part of paid clinical trials in Peoria, Illinois.

Sponsor
OSF Healthcare System
Study ID
NCT00325793
Phase
PHASE4
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Hypertension (high blood pressure) can often cause neurological worsening in patients with stroke, intracerebral hemorrhage and subarachnoid hemorrhage. Intravenous infusion of nicardipine (Cardene) for control of hypertension is FDA approved. The disadvantage of Nicardipine IV drip is the relative large volume of fluid needed (up to 150 cc/hr). The purpose of this study is to evaluate safety and efficacy of double or triple concentrated peripheral intravenous (IV) Nicardipine.

Key Dates

Start date
Jan 31, 2004
Status verified
May 2006

Study Design

Enrollment
50 participants
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

• Demonstrate the feasibility and safety of double and triple concentrated peripheral intravenous Nicardipine for patients in the Neuroscience Critical Care Unit.

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
OSF Stroke CenterPeoriaIllinois61637
David Wang, DO (PRINCIPAL_INVESTIGATOR)

Find similar trials in Peoria, IL

By condition
Hypertension (high blood pressure)
By specialty
CardiologyHeart disease
By research site
OSF Stroke Center· Peoria, IL

Related Studies